US EditionPublished • loading... • Updated
ESMO 2025: J&J Eyes Rybrevant Indication Expansion to HNSCC on Phase II Victory - Pharmaceutical Technology
- Subcutaneous Amivantamab shows a 45 percent overall response rate in patients with recurrent or metastatic head and neck cancer, as reported by Janssen-Cilag International NV.
- The study found that tumor shrinkage occurred in 82 percent of patients, indicating promising efficacy of Amivantamab, according to the data presented at the ESMO 2025 Congress.
- Professor Kevin Harrington noted that these findings may improve treatment options for patients facing aggressive head and neck cancer.
- Janssen-Cilag International NV plans to continue studying Amivantamab in a Phase 3 trial, expanding its evaluation in head and neck cancer treatments.
Insights by Ground AI
33 Articles
33 Articles
Subcutaneous RYBREVANT®▼(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1
·Manila, Philippines
Read Full Article
ESMO 2025: J&J eyes Rybrevant indication expansion to HNSCC on Phase II victory
J&J will now explore Rybrevant's efficacy and safety in a Phase III trial in first-line, EGFR-driven HNSCC and colorectal cancer.The post ESMO 2025: J&J eyes Rybrevant indication expansion to HNSCC on Phase II victory appeared first on Clinical Trials Arena.
Coverage Details
Total News Sources33
Leaning Left1Leaning Right5Center8Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
C 57%
R 36%
Factuality
To view factuality data please Upgrade to Premium
